KA (Kineta Inc) Long-Term Debt

Kineta Inc - graphic logo of issuer KA

The market value dynamics of Kineta, Inc. (KA) demonstrate the impact of patents during early testing stages, which guarantee a prolonged period of intellectual capital value. Kineta, Inc. (KA) is developing advanced antibodies for the detection of resistant tumors, leveraging a robust scientific foundation. However, the current indicator stands at 0.00, as primary developments have been halted due to a funding shortage, and the business value is based on residual rights.

KA Kineta Bio Company Long-Term Liabilities (04/28/2023 - 09/28/2024)

Analytical breakdowns for Kineta Bio (KA)

- price and consensus price forecast:
Price Chart kinetabio.com|KA - Price Target Chart
- market capitalization data:
Market Value Kineta|KA - Enterprise Value
- book capitalization data:
Book Value of One Share Kineta|KA - Company Net Assets|Market-to-Book Ratio kinetabio.com|KA - Cumulative Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Kineta, Inc.|KA - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Kineta Corp|KA - Company Debts|Debt to Book Value Kineta|KA - Company Long-Term Debt|Company Current Liabilities Kineta
Fundamental company valuation:kinetabio.com (KA)
Original product of Kineta, Inc.

Investors must assess the resilience of Kineta, Inc. (KA) within the capital-intensive biopharmaceutical sector. This metric consolidates all obligations with maturities exceeding one year, determining the overall debt load. By analyzing the organization's long-term loans and borrowings, one can track the borrowing trends used to finance the development of anti-cancer drugs. An optimal debt balance ensures the scaling of clinical trials without compromising liquidity. A decrease in this indicator confirms the issuer's financial autonomy.

Competitor analysis for Kineta, Inc.

immunitybio.com - Company Long-Term Debt|IMCR (Immunocore) - Company Long-Term Debt|JANX - Long-Term Debt|Company Long-Term Debts RCUS (Arcus Bio)|Long-Term Indebtedness Zymeworks Biopharmaceuticals|Company Long-Term Liabilities TNGX (Tango Therapeutics)|Long-Term Debt iovance.com (IOVA)|Immatics (IMTX) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings Xencor Inc (XNCR)|Company Long-Term Debts CMPX|Replimune Inc. - Long-Term Debt Volume|LYEL: Company Long-Term Debt|IPHA: Company Long-Term Liabilities|PYXS (pyxisoncology.com) - Company Long-Term Debt|Company Long-Term Liabilities Compugen|IOBT (IO Biotech Corp) - Company Long-Term Liabilities|Company Long-Term Debts STRO|Company Long-Term Debt MiNK Therapeutics, Inc. INKT|Company Long-Term Indebtedness HOWL (werewolftx.com)|IMMX: Company Long-Term Debt|ALXO - Long-Term Debt|Company Long-Term Liabilities CUE|PDS Biotechnology (PDSB) - Long-Term Indebtedness|SONN - Company Long-Term Liabilities|MAIABiotech.com (MAIA) - Amount of Long-Term Liabilities|LIMN - Company Long-Term Debts|Company Long-Term Loans and Borrowings Lava Tx|NextCure Corp - Company Long-Term Debts|Long-Term Debt LPTX (leaptx.com)|Company Long-Term Debt Intensity Therapeutics, Inc.|Company Long-Term Loans and Borrowings Sensei Biotherapeutics Inc SNSE|Theriva Biologics - Company Long-Term Debts|GRTS: Company Long-Term Debts|Company Long-Term Debt NexImmune Corp (NEXI)|Long-Term Liabilities Turnstone Biologics Corp.|Company Long-Term Liabilities VCNX (Vaccinex, Inc.)|Long-Term Debt HARP